Австралия - английски - Department of Health (Therapeutic Goods Administration)

evergrowth pty ltd - ginkgo biloba, quantity: 50 mg (equivalent: ginkgo biloba, qty 2.5 g; equivalent: ginkgolides and bilobalide, qty 3 mg; equivalent: ginkgo flavonglycosides, qty 12 mg) - tablet, film coated - excipient ingredients: hypromellose; colloidal anhydrous silica; povidone; macrogol 400; calcium hydrogen phosphate dihydrate; magnesium stearate; microcrystalline cellulose; crospovidone; carnauba wax - antioxidant/reduce free radicals formed in the body ; maintain/support healthy hearing ; maintain/support general health and wellbeing ; maintain/support healthy blood circulation ; maintain/support blood circulation/flow to the peripheral areas of the body (legs, hands and feet) ; maintain/support blood capillary health ; decrease/reduce/relieve aching/tired legs/leg heaviness associated with mild varicose veins ; maintain/support mental concentration/focus/clarity ; enhance/improve/promote/increase mental alertness/wakefulness ; maintain/support memory/mental recall

Австралия - английски - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin sodium, quantity: 1.06 g (equivalent: amoxicillin, qty 1 g) - injection, powder for - excipient ingredients: - amoxil parenteral is intended for use where the patient's condition precludes the administration of the oral form. it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms: note: therapy should be guided by bacteriological studies, including sensitivity tests, and clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. septicaemia: (bacterial) h. influenzae; e. coli (see microbiology); p.mirabilis; streptococcus; s. pneumoniae; s. faecalis and salmonella typhi. skin and skin structure: staphylococcus, non-penicillinase-producing; streptococcus; e. coli (see microbiology). respiratory, acute and chronic: haemophilus influenzae; streptococcus; s. pneumoniae; staphylococcus, non-penicillinase producing; e. co

Австралия - английски - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - tamoxifen citrate -

Австралия - английски - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin, quantity: 500 mg; clavulanic acid, quantity: 125 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate; dimeticone 5000; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; macrogol 6000; macrogol 4000 - augmentin tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology): urinary tract infections (uncomplicated and complicated); lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis; upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis; skin and skin structure infections. appropriate culture and susceptibility studies should be performed to identify the causative organisms(s) and its (their) susceptibility to augmentin tablets. however, when there is reason to believe an infection may involve any of the b-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and b-lactamase producing organisms susceptible to augmentin tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - betamethasone valerate, quantity: 0.24 mg/g (equivalent: betamethasone, qty 0.2 mg/g) - cream - excipient ingredients: cetomacrogol 1000; cetostearyl alcohol; white soft paraffin; liquid paraffin; purified water; chlorocresol; monobasic sodium phosphate; phosphoric acid; sodium hydroxide - indications as at 23 april 2004 : eczema includiing: atopic, infantile, stasis and discoid eczemas. besnier's (flexural) prurigo. otitis externa. neurodermatoses including lichen simplex, lichen planus. seborrheic dermatitis, contact sensitivity reactions and allergies.

Армения - английски - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pharmacare plc - betahistine (betahistine dihydrochloride) - tablets - 24mg

Армения - английски - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pharmacare plc - betahistine (betahistine dihydrochloride) - tablets - 16mg

Малта - английски - Medicines Authority

pharmacare premium limited hhf 003 halfar industrial estate birzebbugia bbg 3000, malta - capecitabine - film-coated tablet - capecitabine 150 mg - antineoplastic agents

Малта - английски - Medicines Authority

pharmacare premium limited hhf 003 halfar industrial estate birzebbugia bbg 3000, malta - capecitabine - film-coated tablet - capecitabine 500 mg - antineoplastic agents

Малта - английски - Medicines Authority

welding gmbh & co. kg esplanade 39, 20354, hamburg, germany - tadalafil - film-coated tablet - tadalafil 5 milligram(s) - urologicals